Alectinib Drug to Treat Non-Small-Cell Lung Cancer
Lung cancer or lung carcinoma is one of the most common and serious cancers worldwide. Lung cancer occurs due to an uncontrolled growth of abnormal cells either in single or both lungs, which usually affects older people. Patients with anaplastic lymphoma kinase (ALK)-postive non-small-cell lung cancer were treated in two separate groups with alectinib and crizotinib respectively, and found alectinib improved the symptoms of lung cancer much better when compared with crizotinib.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer